VivoSeq
Other

Solid Organ Transplant Recipients

0

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Solid Organ Transplant Recipients is an early-stage landscape with 0 programs across 3 companies. The most active players are Roche, DUSA Pharmaceuticals, Inc., Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

PreclinicalD

DUSA Pharmaceuticals, Inc.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed6 · 46%
Enrolling by invitation2 · 15%
Recruiting2 · 15%
Terminated2 · 15%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Recruiting·TTufts Medical Center·Phase 4·NCT05626530·25 enrolled
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
Recruiting·WWomen's College Hospital·Phase 3·NCT05955924·396 enrolled
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
Active, not recruiting·UUniversity of California, Los Angeles·N/A·NCT01527591·17 enrolled
CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients
Enrolling by invitation·FFernanda P Silveira, MD, MS·Phase 4·NCT07009548·45 enrolled
Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients
Enrolling by invitation·—·Phase 4·NCT06162494·80 enrolled
VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Completed·Roche logoRoche·Phase 4·NCT00431353·325 enrolled
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Completed·Roche logoRoche·Phase 2/3·NCT00090766·63 enrolled
Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
Completed·Pfizer logoPfizer·Phase 3·NCT00037531·769 enrolled
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
Completed·UUniversity of California, San Francisco·Phase 4·NCT02866695·20 enrolled
Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
Completed·RRabin Medical Center·Phase 4·NCT02503982·13 enrolled
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
Completed·MMedical Dermatology Specialists·Phase 1/2·NCT03110159·8 enrolled
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT03950414·2 enrolled
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
Terminated·DDUSA Pharmaceuticals, Inc.·Phase 2·NCT00865878·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)